Werewolf Therapeutics Announces Q2 2026 Financial Results

What Happened

• Werewolf Therapeutics, Inc. (HOWL) filed a Current Report on Form 8-K on July 31, 2026 to announce its quarterly financial results for the quarter ended June 30, 2026. The company issued a press release reporting those results and furnished the press release as Exhibit 99.1 to the 8-K. The filing was signed by Michael J. Urban, Vice President of Finance and Corporate Controller.

Key Details

• Filing date: July 31, 2026; quarter reported: ended June 30, 2026.
• The press release announcing the quarterly results is furnished as Exhibit 99.1 to the Form 8-K.
• The Form 8-K was filed under Item 2.02 (Results of Operations and Financial Condition) and includes standard Item 9.01 exhibits.
• The filing includes a standard cautionary note on forward-looking statements addressing risks and uncertainties.

Why It Matters

• This 8-K notifies investors that Werewolf released its quarterly earnings/financial results; investors should review the press release (Exhibit 99.1) for revenue, expenses, cash runway and other metrics that affect valuation and near-term outlook.
• The forward-looking statements caution reminds investors that projections and plans in the release are subject to risks and may change; the 8-K itself does not change corporate governance or disclose management changes.